Skip to content
Clinical Trials – home
Therapeutic area

Metabolism and nutrition disorders – page 48

  • 741 clinical trials
  • 263 recruiting
  • 237 conditions
  • 26 countries

Conditions in this area

237 conditions with trials, the busiest first

Clinical trials in Metabolism and nutrition disorders

741 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

741 clinical trials

Study of Efgartigimod for Adults with Thyroid Eye Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on INZ-701 for Improving Survival in Infants with ENPP1 Deficiency

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Study on the Effects of ARO-APOC3 for Adults with Familial Chylomicronemia Syndrome

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Study of Avalotcagene Ontaparvovec for Patients Aged 12 and Older with Late-onset Ornithine Transcarbamylase Deficiency

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Arteriosclerosis+2

Not recruiting

Long-term Safety Study of INZ-701 for Patients with ENPP1 and ABCC6 Deficiencies, Including Pseudoxanthoma Elasticum and Generalized Arterial Calcification of Infancy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Hypothyroidism

Not recruiting

Study on Levothyroxine and Sildenafil for Improving Erectile Function in Patients with Subclinical Hypothyroidism and Erectile Dysfunction

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Levothyroxine
  • Sponsor:Asociacion Instituto De Investigacion Sanitaria Biobizkaia

Study on Gene Therapy with Atidarsagene Autotemcel for Patients with Metachromatic Leukodystrophy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Atidarsagene Autotemcel
  • Sponsor:Orchard Therapeutics (Europe) Limited

Study of SPI-62 for Treating ACTH-Dependent Cushing's Syndrome in Patients with Cushing's Disease or Ectopic ACTH/CRH Secretion

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Clofutriben
  • Sponsor:Sparrow Pharmaceuticals Inc.

Study on Long-Term Safety and Efficacy of Cebsulfase Alfa for Children with Late Metachromatic Leukodystrophy Receiving Intrathecal Enzyme Replacement

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Cebsulfase Alfa
  • Sponsor:Shire Human Genetic Therapies Inc.

Hyperglycaemia

Not recruiting

Study of Insulin Treatment for Blood Glucose Control in Adult Critically Ill Patients with Stress Hyperglycemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Human
  • Sponsor:UZ Leuven

Study on the Effects of Ertugliflozin and Sodium Intake on Blood Pressure in Overweight Adults with Type 2 Diabetes

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Ertugliflozin
  • Sponsor:Amsterdam UMC Stichting

Hyperadrenocorticism

Not recruiting

Study of SPI-62 for Treating Cushing's Syndrome in Patients with Benign Adrenal Tumors

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:4-{5-[2-(4-Chloro-2,6-Difluorophenoxy)Propan-2-Yl]-4-Methyl-4H-1,2,4-Triazol-3-Yl}-3-Fluorobenzamide
  • Sponsor:Sparrow Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.